Reduced indinavir exposure during pregnancy. - Wikidata - awgldk - TriplyDB

Reduced indinavir exposure during pregnancy.

Reduced indinavir exposure during pregnancy.

http://www.wikidata.org/entity/Q37161917

about

Pregnancy-Associated Changes in Pharmacokinetics: A Systematic Review Protecting the fetus against HIV infection: a systematic review of placental transfer of antiretrovirals.Expansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19 Prediction of gestational age-dependent induction of in vivo hepatic CYP3A activity based on HepaRG cells and human hepatocytes.Pharmacokinetics of Once Versus Twice Daily Darunavir in Pregnant HIV-Infected Women.Pharmacokinetics of Rilpivirine in HIV-Infected Pregnant Women.Basic obstetric pharmacology.Pharmacogenetics of pregnancy-induced changes in efavirenz pharmacokinetics.

P2860

Q28109657-5A005AC0-6C22-4126-AC0B-E5F1EB675538 Q34429204-16B510BC-A307-4B20-A4E5-1399BD912494 Q35211432-79EBF2D8-4ED7-458C-8FA3-2EA4C4EA1C34 Q35600241-C1AEE215-5120-4771-9DBC-EEB312DF9DDB Q36084313-D8321F30-2D43-414E-B73C-C48EBEEEBF6D Q37013956-80B1E57E-3B01-4DDB-B13F-0FF18B06D4B2 Q38256590-8E08DCC8-CA39-4667-ACED-3AB42CF9CB7B Q46158508-2B9C3612-1263-4EE1-8D30-301ED5BC74CE

P2860

Reduced indinavir exposure during pregnancy.

http://www.wikidata.org/entity/Q37161917

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on September 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Reduced indinavir exposure during pregnancy.

@en

Reduced indinavir exposure during pregnancy.

@nl

type

label

Reduced indinavir exposure during pregnancy.

@en

Reduced indinavir exposure during pregnancy.

@nl

prefLabel

Reduced indinavir exposure during pregnancy.

@en

Reduced indinavir exposure during pregnancy.

@nl

P1433

Q37161917-A01B54E8-D470-47A2-81A1-FC5EEF925BC1

P1476

Q37161917-DC0BA183-B124-4C46-B8FA-B857604AB662

P2093

Q37161917-02987EA8-BE47-48FD-B6D2-244F6A448884

Q37161917-0C0B11E8-386F-4858-B896-8D59C361A6A5

Q37161917-0CE4A288-FEA4-4635-8654-29EC09E805A4

Q37161917-18E64FE7-0F29-4789-8757-ED7693EBCBC4

Q37161917-458E4584-0041-4B58-84D1-14C0800DE52A

Q37161917-4D3DD2B0-B720-4A9F-BACD-2ADDF434E21D

Q37161917-58701EEB-7ADE-4A69-AD3B-85ADA8D995DD

Q37161917-6FA51B62-C1E7-44AD-83D5-C2A631008255

Q37161917-78A9D477-53B1-42EE-BCE3-5535A7E8CA8B

Q37161917-79435D6C-65EF-4545-AE64-C90FCA094CA7

P2860

Q37161917-2CA4EE0A-CF02-4410-8806-44814F20EB19

Q37161917-2DCD1D27-36CA-4961-B55F-C0AF2A921D32

Q37161917-36DA603F-FDE8-4FC6-89DE-75F3E795E2F6

Q37161917-42A5113B-90A0-4EA6-8528-DA9491B0BD28

Q37161917-44B7E0E9-AFF0-425E-9849-6D62A1CEDF06

Q37161917-50A7ED0E-97CB-4CD0-820E-6915DA3809B9

Q37161917-5D5E7212-25B3-4FF5-92EB-20C3E4F49EA5

Q37161917-5FC9906C-4B58-4CD8-8F34-F49F3515265C

Q37161917-712666B9-55BA-4AD0-BEB2-EF1F11D3E896

Q37161917-8F1880A6-CA3D-47AF-B9F2-479E2F241B3F

P304

Q37161917-BA902A69-5D04-48EF-AE69-D78F858AF39C

P31

Q37161917-B77852DC-8BAD-441C-857A-40FAD868CDE7

P356

Q37161917-148347A1-8703-44DD-9485-A80C6E0E26C0

P407

Q37161917-79BAEA16-C23A-49D1-B59A-C0230BB0E14C

P433

Q37161917-565F9AF6-1CC7-4454-83A4-1FC8542EFF6E

P478

Q37161917-BD42155B-29A5-4A24-97CB-44A017C8F140

P50

Q37161917-4435E0B4-99D2-4741-B241-3D2080E03055

Q37161917-EEFB7220-A5BA-41F4-B26D-056F3884CA04

P577

Q37161917-A4DB377E-C614-4851-BC79-45EA91B168C6

P698

Q37161917-880E09CB-CAFC-400B-8B47-68E094878C04

P932

Q37161917-D3B47FBF-20F4-4C7E-8BDB-1F5457837803

P356

P1433

British Journal of Clinical Pharmacology

P1476

Reduced indinavir exposure during pregnancy.

@en

P2093

Alice Stek

http://www.w3.org/2001/XMLSchema#string

Brookie M Best

http://www.w3.org/2001/XMLSchema#string

D Heather Watts

http://www.w3.org/2001/XMLSchema#string

David E Shapiro

http://www.w3.org/2001/XMLSchema#string

Edmund Capparelli

http://www.w3.org/2001/XMLSchema#string

IMPAACT P1026s team

http://www.w3.org/2001/XMLSchema#string

Jiajia Wang

http://www.w3.org/2001/XMLSchema#string

Jullapong Achalapong

http://www.w3.org/2001/XMLSchema#string

Mark Mirochnick

http://www.w3.org/2001/XMLSchema#string

Nantasak Chotivanich

http://www.w3.org/2001/XMLSchema#string

P2860

Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers

Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAART

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.

Influence of body weight on achieving indinavir concentrations within its therapeutic window in HIV-infected Thai patients receiving indinavir boosted with ritonavir.

Atazanavir pharmacokinetics with and without tenofovir during pregnancy

Pharmacokinetics and safety of indinavir in human immunodeficiency virus-infected pregnant women

Lopinavir tablet pharmacokinetics with an increased dose during pregnancy.

Pharmacokinetics of antiretrovirals in pregnant women.

Quality assurance program for clinical measurement of antiretrovirals: AIDS clinical trials group proficiency testing program for pediatric and adult pharmacology laboratories.

Antiretroviral therapy with a twice-daily regimen containing 400 milligrams of indinavir and 100 milligrams of ritonavir in human immunodeficiency virus type 1-infected women during pregnancy

P304

475-483

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BCP.12078

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

76

http://www.w3.org/2001/XMLSchema#string

P50

Regis Kreitchmann

Elizabeth Smith

P577

2013-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23305215

http://www.w3.org/2001/XMLSchema#string

P932

3769674

http://www.w3.org/2001/XMLSchema#string